https://www.enzymatica.com/https://www.enzymatica.com/corporate-governance/corporate-governance/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2016/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2017/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2018/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2019/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2020/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2021/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2022/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2023/https://www.enzymatica.com/corporate-governance/corporate-governance/corporate-governance-report-2024/https://www.enzymatica.com/corporate-governance/annual-general-meetings/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2013/annual-general-meeting-2013/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2014/extraordinary-general-meeting-2014-03-06/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2014/annual-general-meeting-2014/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2014/extraordinary-general-meeting-2014-12-19/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2015/annual-general-meeting-2015/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2016/extraordinary-general-meeting-februari-15-2016/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2016/extraordinary-general-meeting-april-14-2016/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2016/annual-general-meeting-2016/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2016/extraordinary-general-meeting-december-19-2016/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2017/annual-general-meeting-2017/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2017/extraordinary-general-meeting-october-25-2017/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2018/annual-general-meeting-2018/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2018/extraordinary-general-meeting-november-5-2018/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2019/annual-general-meeting-2019/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2020/annual-general-meeting-2020/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2021/annual-general-meeting-2021/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2021/extraordinary-general-meeting-october-18-2021/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2022/annual-general-meeting-2022/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2023/annual-general-meeting-2023/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2024/annual-general-meeting-2024/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2024/extra-general-meeting-2024/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2025/annual-general-meeting-2025/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2025/extra-general-meeting-2025/https://www.enzymatica.com/corporate-governance/annual-general-meetings/2026/annual-general-meeting-2026/https://www.enzymatica.com/corporate-governance/nomination-committee/https://www.enzymatica.com/corporate-governance/board-of-directors/https://www.enzymatica.com/corporate-governance/remuneration-guidelines/https://www.enzymatica.com/corporate-governance/articles-of-association/https://www.enzymatica.com/science/independent-studies/https://www.enzymatica.com/science/research-milestones/https://www.enzymatica.com/products/coldzyme/https://www.enzymatica.com/products/enzyme-formulation/https://www.enzymatica.com/research-development-lp/https://www.enzymatica.com/company/introduction/https://www.enzymatica.com/company/organisation/https://www.enzymatica.com/company/history/https://www.enzymatica.com/company/code-of-conduct/https://www.enzymatica.com/company/sustainability/https://www.enzymatica.com/privacy-policy/https://www.enzymatica.com/media/press-releases/https://www.enzymatica.com/media/press-releases/2026/year-end-report-2025-new-ceo-takes-the-helm-initiates-the-next-phase-of-enzymaticas-international-expansion/https://www.enzymatica.com/media/press-releases/2026/notice-of-annual-general-meeting-2026-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2026/enzymatica-and-stada-sign-partnership-agreement-for-germany-and-austria/https://www.enzymatica.com/media/press-releases/2025/enzymatica-appoints-acting-cfo-during-transition-period/https://www.enzymatica.com/media/press-releases/2025/enzymatica-enters-partnership-with-the-uk-sports-institute-to-support-athlete-health-and-performance/https://www.enzymatica.com/media/press-releases/2025/enzymatica-to-support-swedish-biathlon-federation-as-official-supplier/https://www.enzymatica.com/media/press-releases/2025/quarterly-report-q32025-strong-development-in-sweden-and-continued-focus-on-international-expansion/https://www.enzymatica.com/media/press-releases/2025/enzymatica-strengthens-its-presence-in-elite-sports-announces-partnership-with-gb-snowsport/https://www.enzymatica.com/media/press-releases/2025/coldzyme-launches-a-refreshing-new-flavour-eucalyptus/https://www.enzymatica.com/media/press-releases/2025/enzymatica-appoints-holger-lembrer-as-new-cfo/https://www.enzymatica.com/media/press-releases/2025/enzymaticas-cfo-therese-filmersson-to-leave-her-position/https://www.enzymatica.com/media/press-releases/2025/claus-egstrand-steps-down-as-ceo-of-enzymatica/https://www.enzymatica.com/media/press-releases/2025/bulletin-from-the-annual-general-meeting-of-enzymatica-ab-publ-on-may-7-2025/https://www.enzymatica.com/media/press-releases/2025/quarterly-report-q12025-enzymatica-strengthens-its-position-in-home-markets-and-focuses-on-international-expansion/https://www.enzymatica.com/media/press-releases/2025/enzymatica-publishes-annual-report-for-2024/https://www.enzymatica.com/media/press-releases/2025/notice-of-annual-general-meeting-2025-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2025/replay-link-to-digital-press-briefing-march-5-2025/https://www.enzymatica.com/media/press-releases/2025/invitation-to-press-briefing-5-march-2025/https://www.enzymatica.com/media/press-releases/2025/bulletin-from-the-extraordinary-general-meeting-of-enzymatica-ab-publ-on-22-august-2025/https://www.enzymatica.com/media/press-releases/2025/sana-alajmovic-appointed-new-ceo-of-enzymatica-ab/https://www.enzymatica.com/media/press-releases/2025/notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2025/quarterly-report-q22025-strong-development-in-sweden-and-increased-international-activity/https://www.enzymatica.com/media/press-releases/2025/enzymatica-focuses-on-growth-with-new-recruitment-anna-soderlund-joins-as-senior-director-marketing-sales/https://www.enzymatica.com/media/press-releases/2025/year-end-report-2024-strong-performance-in-core-markets-preparing-for-international-growth/https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/https://www.enzymatica.com/media/press-releases/2024/final-results-from-independent-clinical-study-of-coldzyme-show-duration-of-illness-lowered-by-approximately-5-days-/https://www.enzymatica.com/media/press-releases/2024/enzymatica-announces-outcome-of-new-rights-issue/https://www.enzymatica.com/media/press-releases/2024/coldzyme-certified-under-the-new-eu-medical-device-regulation-mdr/https://www.enzymatica.com/media/press-releases/2024/enzymatica-publishes-information-memorandum-about-rights-issue-of-shares/https://www.enzymatica.com/media/press-releases/2024/enzymaticas-rights-issue-is-secured-to-100-percent/https://www.enzymatica.com/media/press-releases/2024/notice-of-annual-general-meeting-2024-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2024/year-end-report-2023-scientific-and-regulatory-progress-generating-international-interest/https://www.enzymatica.com/media/press-releases/2024/enzymaticas-board-of-directors-updates-the-financial-targets/https://www.enzymatica.com/media/press-releases/2024/notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2024/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-approximately-sek-130-million/https://www.enzymatica.com/media/press-releases/2024/interim-results-from-independent-clinical-study-of-coldzyme-show-duration-of-illness-lowered-by-approximately-5-days/https://www.enzymatica.com/media/press-releases/2024/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-may-7-2024/https://www.enzymatica.com/media/press-releases/2024/interim-report-q12024-mdr-certification-opens-up-great-commercial-opportunities/https://www.enzymatica.com/media/press-releases/2024/bulletin-from-the-extraordinary-general-meeting-of-enzymatica-ab-publ-on-6-august-2024/https://www.enzymatica.com/media/press-releases/2024/enzymatica-publishes-annual-report-for-2023/https://www.enzymatica.com/media/press-releases/2024/interim-report-q32024-focus-on-developing-existing-and-new-markets/https://www.enzymatica.com/media/press-releases/2024/publication-of-prospectus-regarding-enzymaticas-rights-issue/https://www.enzymatica.com/media/press-releases/2024/interim-report-q22024-enzymatica-builds-momentum-for-expansion/https://www.enzymatica.com/media/press-releases/2024/reported-results-on-secondary-endpoints-from-the-university-of-kent-study-on-coldzyme-show-significant-reduction-of-symptoms-lost-training-days-and-viral-load/https://www.enzymatica.com/media/press-releases/2024/enzymatica-publishes-supplementary-prospectus/https://www.enzymatica.com/media/press-releases/2024/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-27-4-million/https://www.enzymatica.com/media/press-releases/2023/enzymatica-changes-certified-adviser-to-carnegie-investment-bank-ab-publ/https://www.enzymatica.com/media/press-releases/2023/notice-of-annual-general-meeting-2023-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2023/interim-report-q42022-a-year-that-laid-the-foundation-for-growth/https://www.enzymatica.com/media/press-releases/2023/enzymatica-publishes-annual-report-for-2022/https://www.enzymatica.com/media/press-releases/2023/interim-report-q32023-research-results-that-reshape-the-competitive-landscape/https://www.enzymatica.com/media/press-releases/2023/interim-report-from-clinical-study-coldzyme-significantly-reduces-rhinovirus-viral-load-and-symptoms-of-sore-throat/https://www.enzymatica.com/media/press-releases/2023/new-study-coldzyme-breaks-viral-infection-cycle--significantly-reducing-influenza-viral-load/https://www.enzymatica.com/media/press-releases/2023/interim-report-q22023-an-exciting-and-important-time-ahead/https://www.enzymatica.com/media/press-releases/2023/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2023/interim-report-q12023-strong-start-to-the-year--enzymaticas-growth-journey-continues-according-to-plan/https://www.enzymatica.com/media/press-releases/2022/enzymatica-and-university-of-kent-launch-study-to-explore-prevention-of-upper-respiratory-virus-infections-in-elite-athletes/https://www.enzymatica.com/media/press-releases/2022/interim-report-q32022-a-broader-role-for-coldzyme-adds-potential-for-the-future/https://www.enzymatica.com/media/press-releases/2022/new-study-confirms-coldzyme-stops-viruses-causing-covid-19-from-adhering-to-human-respiratory-cells/https://www.enzymatica.com/media/press-releases/2022/enzymatica-announces-outcome-of-new-rights-issue/https://www.enzymatica.com/media/press-releases/2022/enzymatica-publishes-supplementary-prospectus/https://www.enzymatica.com/media/press-releases/2022/coldzyme-also-blocks-omicron-variants-ba4-and-ba5/https://www.enzymatica.com/media/press-releases/2022/publication-of-prospectus-regarding-enzymaticas-rights-issue/https://www.enzymatica.com/media/press-releases/2022/interim-report-q22022-improved-sales-give-confidence-for-the-future/https://www.enzymatica.com/media/press-releases/2022/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-747-million/https://www.enzymatica.com/media/press-releases/2022/coldzyme-blocks-omicron-virus--according-to-new-research/https://www.enzymatica.com/media/press-releases/2022/enzymatica-signs-loan-agreement-with-major-shareholders/https://www.enzymatica.com/media/press-releases/2022/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-28-april-2022/https://www.enzymatica.com/media/press-releases/2022/interim-report-q12022-our-financial-targets-remain-in-place/https://www.enzymatica.com/media/press-releases/2022/article-about-coldzyme-acquitted-from-suspicions-of-research-misconduct/https://www.enzymatica.com/media/press-releases/2022/enzymaticas-mouth-spray-to-be-launched-in-turkey/https://www.enzymatica.com/media/press-releases/2022/enzymatica-publishes-annual-report-for-2021/https://www.enzymatica.com/media/press-releases/2022/notice-of-annual-general-meeting-2022-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2022/enzymaticas-mouth-spray-to-be-launched-in-mexico/https://www.enzymatica.com/media/press-releases/2022/year-end-report-clear-signs-of-favourable-market-trends-after-a-challenging-2021/https://www.enzymatica.com/media/press-releases/2022/enzymatica-comments-on-wrongful-wording-in-dagens-medicin/https://www.enzymatica.com/media/press-releases/2021/the-long-term-plan-remains-in-challenging-times/https://www.enzymatica.com/media/press-releases/2021/enzymatica-board-decides-on-financial-targets/https://www.enzymatica.com/media/press-releases/2021/bulletin-from-the-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2021/notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2021/claus-egstrand-takes-office-as-ceo-ahead-of-schedule/https://www.enzymatica.com/media/press-releases/2021/chinese-and-us-patent-authorities-issue-notices-of-allowance-for-patent-for-key-component-in-cold-spray-coldzyme/https://www.enzymatica.com/media/press-releases/2021/continued-lower-sales-due-to-pandemic-but-some-stabilization/https://www.enzymatica.com/media/press-releases/2021/claus-egstrand-appointed-new-ceo-of-enzymatica/https://www.enzymatica.com/media/press-releases/2021/enzymatica-and-stada-extend-agreement-on-viruprotect-to-vietnam/https://www.enzymatica.com/media/press-releases/2021/enzymatica-appoints-new-director-of-quality-assurance-and-communication-manager/https://www.enzymatica.com/media/press-releases/2021/enzymatica-announces-outcome-of-new-rights-issue/https://www.enzymatica.com/media/press-releases/2021/enzymatica-launches-coldzyme-on-amazon/https://www.enzymatica.com/media/press-releases/2021/patent-for-coldzyme-approved-in-japan/https://www.enzymatica.com/media/press-releases/2021/prospectus-for-enzymaticas-rights-issue-is-published/https://www.enzymatica.com/media/press-releases/2021/bulletin-from-annual-general-meeting-of-enzymatica-ab-publ-on-5-may-2021/https://www.enzymatica.com/media/press-releases/2021/lower-sales-due-to-the-pandemic-but-new-rights-issue-secures-continued-international-expansion/https://www.enzymatica.com/media/press-releases/2021/enzymatica-publication-of-the-annual-report-2020/https://www.enzymatica.com/media/press-releases/2021/notice-of-annual-general-meeting-2021-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2021/enzymaticas-board-of-directors-decides-on-a-new-rights-issue-of-sek-591-million/https://www.enzymatica.com/media/press-releases/2021/enzymaticas-sales-and-result-affected-by-the-pandemic/https://www.enzymatica.com/media/press-releases/2021/positive-operating-result-and-almost-doubled-sales-for-the-fourth-quarter/https://www.enzymatica.com/media/press-releases/2021/enzymatica-comments-on-article-in-dagens-medicin/https://www.enzymatica.com/media/press-releases/2021/new-strategic-recruitments-and-organizational-changes-at-enzymatica/https://www.enzymatica.com/media/press-releases/2020/stada-agreement-extended-for-the-nordic-region/https://www.enzymatica.com/media/press-releases/2020/enzymatica-enters-agreement-with-ms-pharma-for-mena/https://www.enzymatica.com/media/press-releases/2020/continued-strong-sales-increase-and-positive-cash-flow-in-third-quarter/https://www.enzymatica.com/media/press-releases/2020/enzymatica-enters-agreement-with-sanofi-for-covering-france-and-italy-on-common-cold-spray-coldzyme/https://www.enzymatica.com/media/press-releases/2020/enzymatica-and-stada-extend-agreement-on-viruprotect-to-russia-poland-ukraine-and-cis-countries/https://www.enzymatica.com/media/press-releases/2020/coldzyme-launched-in-israel/https://www.enzymatica.com/media/press-releases/2020/the-journal-of-medical-virology-has-peer-reviewed-approved-and-published-the-results-of-enzymaticas-in-vitro-study-on-sars-cov-2/https://www.enzymatica.com/media/press-releases/2020/new-patents-approved-for-coldzyme-in-japan-and-russia/https://www.enzymatica.com/media/press-releases/2020/new-version--corrected-17-september-2020-the-results-of-enzymaticas-placebo-controlled-randomized-study/https://www.enzymatica.com/media/press-releases/2020/the-results-of-enzymaticas-placebo-controlled-randomized-study-show-statistically-significant-shorter-common-colds-and-good-treatment-efficacy-when-using-coldzyme/https://www.enzymatica.com/media/press-releases/2020/a-new-in-vitro-study-shows-the-ability-of-coldzyme-to-deactivate-sars-cov-2-the-cause-of-the-covid-19-pandemic/https://www.enzymatica.com/media/press-releases/2020/doubled-sales-also-during-the-second-quarter/https://www.enzymatica.com/media/press-releases/2020/shorter-duration-of-common-colds-for-endurance-athletes-with-coldzyme/https://www.enzymatica.com/media/press-releases/2020/enzymatica-and-stada-extend-agreement-for-europe/https://www.enzymatica.com/media/press-releases/2020/grant-of-european-patent-for-coldzyme/https://www.enzymatica.com/media/press-releases/2020/changes-in-management-at-enzymatica/https://www.enzymatica.com/media/press-releases/2020/bulletin-from-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2020/doubled-sales-and-positive-earnings-for-the-first-quarter/https://www.enzymatica.com/media/press-releases/2020/coldzyme-re-certified-to-class-iii-in-the-eu/https://www.enzymatica.com/media/press-releases/2020/enzymatica-enables-postal-voting-at-the-annual-general-meeting-2020/https://www.enzymatica.com/media/press-releases/2020/notice-of-annual-general-meeting-2020-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2020/enzymatica---publication-of-the-annual-report-2019/https://www.enzymatica.com/media/press-releases/2020/enzymatica-gets-increased-sales-due-to-the-corona-situation/https://www.enzymatica.com/media/press-releases/2020/enzymatica-signs-agreement-with-chemipal-for-israel/https://www.enzymatica.com/media/press-releases/2020/strong-results-from-preventive-use-of-coldzyme-against-common-cold-virus/https://www.enzymatica.com/media/press-releases/2020/coldzyme--third-largest-cold-brand-in-sweden/https://www.enzymatica.com/media/press-releases/2020/shorter-colds-and-milder-symptoms-among-children-who-use-coldzyme/https://www.enzymatica.com/media/press-releases/2020/the-european-patent-office-recommends-grant-of-a-new-patent-covering-a-key-ingredient-in-coldzyme-against-the-common-cold/https://www.enzymatica.com/media/press-releases/2020/the-nomination-committee-proposes-that-fredrik-lindberg-is-elected-to-the-board-of-directors/https://www.enzymatica.com/media/press-releases/2020/enzymatica-signs-agreement-with-keyuan-trade-for-china/https://www.enzymatica.com/media/press-releases/2020/coldzyme-launched-in-hong-kong/https://www.enzymatica.com/media/press-releases/2019/enzymaticas-ceo-resigns/https://www.enzymatica.com/media/press-releases/2019/enzymatica-in-agreement-for-enzyme-formulations-for-the-chinese-skin-care-market/https://www.enzymatica.com/media/press-releases/2019/stada-collaboration-expands-in-germany/https://www.enzymatica.com/media/press-releases/2019/very-strong-increase-of-sales-during-the-third-quarter/https://www.enzymatica.com/media/press-releases/2019/enzymatica-recruits-new-director-of-quality-assurance/https://www.enzymatica.com/media/press-releases/2019/preliminary-results-of-enzymaticas-placebo-controlled-randomized-study-did-not-meet-the-primary-end-point/https://www.enzymatica.com/media/press-releases/2019/coldzyme-launches-with-new-flavor-and-new-product-claims/https://www.enzymatica.com/media/press-releases/2019/good-growth-in-q2-driven-mainly-by-strong-sales-in-sweden/https://www.enzymatica.com/media/press-releases/2019/enzymatica-signs-supply-agreement-with-german-cosmetic-company-maren-amounting-to-a-value-of-sek-120-million-over-a-period-of-three-years/https://www.enzymatica.com/media/press-releases/2019/bulletin-from-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2019/continued-strong-growth-in-sweden-but-lower-total-sales-during-the-quarter/https://www.enzymatica.com/media/press-releases/2019/all-patients-enrolled-in-enzymaticas-german-placebo-controlled-multicentre-study-with-coldzyme/https://www.enzymatica.com/media/press-releases/2019/enzymaticas-cold-spray-launched-in-south-africa/https://www.enzymatica.com/media/press-releases/2019/enzymatica-ab-strong-sales-in-the-fourth-quarter-but-lower-sales-for-full-year-2018-driven-by-restrictions-in-germany/https://www.enzymatica.com/media/press-releases/2019/enzymatica-ab-first-patients-included-in-large-placebo-controlled-multicentre-study-on-coldzyme/https://www.enzymatica.com/media/press-releases/2019/multi-symptom-relief-and-improvement-of-quality-of-life---a-comparative-multicenter-trial-on-coldzyme-mouth-spray-in-common-cold/https://www.enzymatica.com/media/press-releases/2019/enzymatica-ab-results-from-german-multicentre-study-strengthen-and-broaden-coldzymes-product-claims/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-appeal-on-enzymaticas-cold-spray-in-germany-overruled/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymatica-raises-sek-987-million-in-completed-share-issue/https://www.enzymatica.com/media/press-releases/2018/enzymatica-signs-another-agreement-in-asia-with-evergreen-for-hong-kong-and-macau/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-prospectus-for-enzymaticas-rights-issue-with-preferential-rights-for-existing-shareholders-published/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymaticas-rights-issue-is-secured-up-to-100-percent/https://www.enzymatica.com/media/press-releases/2018/new-british-study-of-endurance-athletes-shows-reduced-duration-of-colds-with-coldzyme/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-breakthrough-agreement-for-japan-and-lower-sales-in-q3-due-to-restrictions-in-germany/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-notice-of-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-the-board-of-directors-of-enzymatica-ab-decides-on-rights-issue-of--sek-987-million/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-for-the-japanese-market/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-significant-benefits-from-coldzyme-in-a-major-german-multicenter-study-evaluating-different-common-cold-symptom-scales/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-appeal-of-court-ruling-on-enzymaticas-cold-spray-in-germany/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-for-coldzyme-with-abex-pharmaceutica-pty-ltd-for-south-africa/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-lower-sales-in-q2-but-31-increase-for-the-first-half-of-the-year/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-court-ruling-put-restrictions-on-marketing-of-enzymaticas-cold-spray-in-germany/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymatica-secures-funding-for-operations/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymatica-signs-agreement-with-qualia-pharma-for-greece-and-cyprus/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-bulletin-from-annual-general-meeting-2018-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-continued-growth-during-the-first-quarter/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-new-results-from-enzymaticas-in-vitro-study-coldzyme-also-deactivates-corona-virus/https://www.enzymatica.com/media/press-releases/2018/stefansson-et-al-coldzyme-forms-a-protective-barrier-in-the-throat-that-deactivates-five-major-common-cold-viruses-congress-of-the-swedish-association-of-otolaryngology-2018_abstract/https://www.enzymatica.com/media/press-releases/2018/stefansson-et-al-coldzyme-forms-a-protective-barrier-in-the-throat-that-deactivates-five-major-common-cold-viruses-congress-of-the-swedish-association-of-otolaryngology-2018_poster/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-new-coldzyme-study-in-elite-athletes-confirms-preventive-effect-and-reduced-duration-of-illness/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-enzymatica---publication-of-the-annual-report-2017/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-notice-of-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2018/enzymatica-ab-strong-growth-and-international-breakthrough-in-2017/https://www.enzymatica.com/media/press-releases/2017/new-customer-survey--coldzyme-prevents-colds-and-reduces-severity-and-duration-among-cold-sufferers/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-enzymaticas-nomination-committee-for-the-annual-general-meeting-2018-appointed/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-enzymatica-announces-a-study-showing-the-ability-of-coldzyme-to-deactivate-major-common-cold-viruses/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-coldzyme-study---most-recommended-cold-product-at-pharmacies/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-interim-report-for-enzymatica-ab-publ-january-september-2017/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-complete-article-from-coldprev-i-study-published---strengthens-documentation-for-coldzyme/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-coldzyme-cold-spray-reduces-sickness-absence-among-preschool-staff/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-notice-of-extraordinary-general-meeting-regarding-among-other-things-personnel-option-program-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2017/enzymatica-recruits-chief-financial-officer/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-continued-sales-growth-and-breakthrough-order-from-stada/https://www.enzymatica.com/media/press-releases/2017/enzymatica-recruits-chief-commercial-officer/https://www.enzymatica.com/media/press-releases/2017/enzymatica-recruits-chief-operating-officer/https://www.enzymatica.com/media/press-releases/2017/a-study-of-elite-athletes-shows-that-coldzyme-provides-protection-as-evidenced-by-fewer-sick-days-and-lost-training-days-as-well-as-improved-quality-of-life/https://www.enzymatica.com/media/press-releases/2017/enzymatica-receives-record-order-from-stada-arzneimittel-ag/https://www.enzymatica.com/media/press-releases/2017/bengt-jondell-continues-as-acting-cfo/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-bulletin-from-annual-general-meeting-2017-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-breakthrough-in-germany-and-continued-increase-in-sales/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-enzymatica---publication-of-the-annual-report-2016/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-completing-the-nomination-committees-in-enzymatica-ab-proposal-for-agm-2017-regarding-election-of-auditor/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-notice-of-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-geographic-expansion-and-continued-growth-in-2016/https://www.enzymatica.com/media/press-releases/2017/enzymatica-ab-enzymatica-enters-into-partnership-agreement-with-stada-arzneimittel-ag/https://www.enzymatica.com/media/press-releases/2016/coldzyme-demonstrates-reduced-sick-leave-during-cold-season/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-top-line-results-of-new-clinical-trial/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-bulletin-from-extraordinary-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-extraordinary-shareholders-meeting-on-changes-to-the-board-of-directors/https://www.enzymatica.com/media/press-releases/2016/medical-case-report-on-promising-treatment-with-coldzyme-of-patients-with-primary-immunodeficiency/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-coldzyme-sales-continue-to-perform-well/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-enzymatica-signs-distribution-agreement-with-endeavour-consumer-health/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-the-board-of-directors-in-enzymatica-has-resolved-on-a-directed-share-issue-of-sek-403-million/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-excellent-volume-growth-for-coldzyme/https://www.enzymatica.com/media/press-releases/2016/bulletin-from-the-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2016/enzymaticas-new-rights-issue-completed---will-be-provided-with-sek-60-million/https://www.enzymatica.com/media/press-releases/2016/enzymatica-insiders-plan-to-subscribe-for-sek-16-million-in-new-issue/https://www.enzymatica.com/media/press-releases/2016/customer-studies-coldzyme-users-fight-colds-early-and-actively/https://www.enzymatica.com/media/press-releases/2016/notice-of-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2016/enzymatica-publishes-prospectus/https://www.enzymatica.com/media/press-releases/2016/information-about-enzymaticas-new-rights-issue/https://www.enzymatica.com/media/press-releases/2016/enzymatica---publication-of-the-annual-report-2015/https://www.enzymatica.com/media/press-releases/2016/interim-report-for-enzymatica-ab-publ-january-march-2016/https://www.enzymatica.com/media/press-releases/2016/bulletin-from-the-extraordinary-shareholders-meeting-in-enzymatica/https://www.enzymatica.com/media/press-releases/2016/enzymatica-completes-acquisition-of-zymetech-and-includes-new-board-members-and-representative-to-the-nomination-committee/https://www.enzymatica.com/media/press-releases/2016/acting-cfo-of-enzymatica-appointed/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-updated-time-plan-for-the-acquisition-of-zymetech-and-the-rights-issue/https://www.enzymatica.com/media/press-releases/2016/enzymatica-announces-new-dates-for-its-financial-information/https://www.enzymatica.com/media/press-releases/2016/notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2016/the-board-of-directors-in-enzymatica-has-resolved-on-a-rights-issue-of-sek-60-million/https://www.enzymatica.com/media/press-releases/2016/enzymatica-ab-strong-growth-in-2015-and-acquisition-for-international-expansion/https://www.enzymatica.com/media/press-releases/2016/bulletin-from-the-extraordinary-shareholders-meeting-in-enzymatica-2016-02-15/https://www.enzymatica.com/media/press-releases/2016/enzymatica-moves-forward-its-year-end-report-for-2015/https://www.enzymatica.com/media/press-releases/2016/notice-of-extraordinary-shareholders-meeting-in-enzymatica-ab-publ-2016-01-28/https://www.enzymatica.com/media/press-releases/2016/enzymatica-signs-acquisition-agreement-and-prepares-for-international-expansion-with-new-share-issue/https://www.enzymatica.com/media/press-releases/2016/frequently-asked-questions-and-answers-about-enzymaticas-acquisition-of-zymetech/https://www.enzymatica.com/media/press-releases/2016/questions-and-answers--regarding-the-asa-decision-for-marketing--and-web-material-of-coldzyme-in-the-uk/https://www.enzymatica.com/media/press-releases/2015/enzymatica-signs-distribution-agreement-with-esteve-in-spain/https://www.enzymatica.com/media/press-releases/2015/enzymatica-signs-distribution-agreement-with-tamro-for-the-finnish-market/https://www.enzymatica.com/media/press-releases/2015/enzymatica-strengthens-its-presence-in-the-uk-through-collaboration-with-the-lloyds-pharmacy-chain/https://www.enzymatica.com/media/press-releases/2014/fredrik-lindberg-appointed-ceo-of-enzymatica/https://www.enzymatica.com/media/press-releases/2014/launch-in-denmark-expands-coldzyme-to-all-of-scandinavia/https://www.enzymatica.com/media/press-releases/2014/new-chairman-of-the-board-at-enzymatica/https://www.enzymatica.com/media/press-releases/2014/enzymatica-appoints-acting-ceo/https://www.enzymatica.com/media/press-releases/2014/enzymaticas-veterinary-products-launched-at-the-avma-annual-convention-in-denver-usa/https://www.enzymatica.com/media/press-releases/2014/enzymatica-coldzyme-to-be-introduced-in-the-uk/https://www.enzymatica.com/media/press-releases/2014/enzymatica-coldzyme-to-be-introduced-at-pharmacies-in-norway/https://www.enzymatica.com/media/press-releases/2014/enzymatica-presents-coldprev-study-at-scientific-congress-in-copenhagen/https://www.enzymatica.com/media/press-releases/2014/bulletin-from-the-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2014/clarification-shareholder-proposals-for-the-2014-annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2014/enzymaticas-2013-annual-report-now-available/https://www.enzymatica.com/media/press-releases/2014/new-date-for-enzymaticas-interim-report-january-march-may-19-2014/https://www.enzymatica.com/media/press-releases/2014/enzymaticas-rights-issue-oversubscribed/https://www.enzymatica.com/media/press-releases/2014/enzymatica-signs-agreement-for-the-sale-of-coldzyme-at-swedish-airports/https://www.enzymatica.com/media/press-releases/2014/enzymatica-announces-launch-plan-for-a-proprietary-mouthwash-for-gingivitis/https://www.enzymatica.com/media/press-releases/2014/enzymatica-strengthens-its-organisation/https://www.enzymatica.com/media/press-releases/2013/enzymatica-increases-turnover-of-2013--far-beyond-its-financial-goal/https://www.enzymatica.com/media/press-releases/2013/enzymatica-expands-its-own-scandinavian-operation-and-moves-internationally-with-partners/https://www.enzymatica.com/media/press-releases/2013/enzymatica-gets-full-market-coverage-through-wholesale-agreement-with-tamro/https://www.enzymatica.com/media/press-releases/2013/enzymatica-to-offer-new-product-line-and-sets-up-a-subsidiary-in-the-usa/https://www.enzymatica.com/media/press-releases/2013/enzymatica-coldzyme-mouth-spray-on-pharmacy-chain-medstops-shelves/https://www.enzymatica.com/media/press-releases/2013/enzymatica-conducts-a-directed-issue-totalling-sek-19-million/https://www.enzymatica.com/media/press-releases/2013/the-coldprev-study-coldzyme-mouth-spray-reduces-both-the-viral-load-and-the-number-of-sick-days-with-common-cold-in-infected-individuals-compared-with-placebo/https://www.enzymatica.com/media/press-releases/2013/broad-launch-for-coldzyme-mouth-spray-soon-on-apoteket-abs-shelves/https://www.enzymatica.com/media/press-releases/2013/enzymatica-signs-agreement-with-actavis-for-coldzyme-in-the-nordic-region/https://www.enzymatica.com/media/press-releases/2013/annual-general-meeting-in-enzymatica-ab-publ/https://www.enzymatica.com/media/press-releases/2013/enzymatica-starts-the-process-for-listing-on-the-stockholm-stock-exchange/https://www.enzymatica.com/media/press-releases/2013/anders-jungbeck-proposed-as-new-member-of-the-board-of-enzymatica/https://www.enzymatica.com/media/press-releases/2013/christian-w-jansson-is-proposed-as-the-new-chairman-of-the-board-of-enzymatica/https://www.enzymatica.com/media/press-releases/2013/new-date-for-enzymaticas-annual-general-meeting/https://www.enzymatica.com/media/press-releases/2013/enzymatica-to-commence-clinical-market-monitoring-study-for-the-prevention-and-shortening-of-upper-airway-infection/https://www.enzymatica.com/media/press-releases/2013/enzymatica-coldzyme-mouth-spray--for-treating-the-common-cold--to-be-introduced-by-the-swedish-apotek-hjartat-pharmacy-chain/https://www.enzymatica.com/media/press-releases/2012/enzymatica-published-in-the-international-journal-infectious-diseases--therapy--promising-method-for-the-prevention-of-colds-using-coldzyme-mouth-spray/https://www.enzymatica.com/media/press-releases/2012/enzymatica-signs-agreement-with-the-kronans-droghandel-pharmacy-chain/https://www.enzymatica.com/media/press-releases/2012/enzymatica-announces-fredrik-hakansson-as-its-new-cfo/https://www.enzymatica.com/media/press-releases/2012/mats-clarsund-new-evp-research--development-at-enzymatica/https://www.enzymatica.com/media/press-releases/2012/enzymatica-inaugurates-scientific-advisory-board/https://www.enzymatica.com/media/press-releases/2012/enzymaticas-coldzyme-mouth-spray-against-common-cold-is-registered-with-the-swedish-medical-product-agency/https://www.enzymatica.com/media/articles-insights/https://www.enzymatica.com/media/articles-insights/launch-in-mexico/https://www.enzymatica.com/media/articles-insights/launch-in-turkey/https://www.enzymatica.com/media/articles-insights/marketing-campaign-in-sweden/https://www.enzymatica.com/media/articles-insights/interview-with-ceo-claus-egstrand/https://www.enzymatica.com/media/articles-insights/positive-results-from-new-study-on-influenza/https://www.enzymatica.com/media/articles-insights/interview-with-prof-doris-wilflingseder-on-her-new-study-on-coldzyme/https://www.enzymatica.com/media/articles-insights/coldzyme-reduces-rhinovirus-viral-load-and-sore-throat-symptoms-according-to-new-study/https://www.enzymatica.com/media/articles-insights/coldzyme-featured-in-the-us-morning-show-the-balancing-act/https://www.enzymatica.com/media/articles-insights/a-decade-of-coldzyme-advertising/https://www.enzymatica.com/media/articles-insights/results-presented-olympic/https://www.enzymatica.com/media/articles-insights/abstract-published-bjsm/https://www.enzymatica.com/media/articles-insights/enzymatica-part-of-the-global-health-campaign/https://www.enzymatica.com/media/articles-insights/professor-glen-davison-presented-at-global-health-summit/https://www.enzymatica.com/media/articles-insights/biostock-on-the-reported-final-study-results-coldzyme-shortens-the-duration-of-illness-and-relieves-symptoms/https://www.enzymatica.com/media/articles-insights/powered-by-penzyme/https://www.enzymatica.com/media/articles-insights/enzymaticas-ceo-comments-on-sbus-report/https://www.enzymatica.com/media/articles-insights/enzymaticas-results-published-in-the-journal-of-physiology/https://www.enzymatica.com/media/articles-insights/replay-of-the-press-conference-on-coldzyme-march-5-2025/https://www.enzymatica.com/media/articles-insights/an-article-munsprej-applicerad-i-svalget-en-effektiv-behandling-vid-forkylning/https://www.enzymatica.com/media/articles-insights/interview-with-ceo-claus-egstrand-on-q12025-by-biostock/https://www.enzymatica.com/media/articles-insights/ceo-claus-egstrand-presented-enzymatica-at-redeyes-theme-day-on-medtech-/https://www.enzymatica.com/media/articles-insights/the-professors-behind-the-coldzyme-studies-interviewed-by-biostock/https://www.enzymatica.com/media/articles-insights/new-coldzyme-website-with-a-focus-on-science-and-understanding-the-common-cold/https://www.enzymatica.com/media/articles-insights/enzymatica-enters-new-partnership-with-the-swedish-biathlon-federation/https://www.enzymatica.com/media/articles-insights/beat-the-cold-faster-coldzymes-new-campaign/https://www.enzymatica.com/media/articles-insights/enzymatica-launches-coldzyme-eucalyptus/https://www.enzymatica.com/media/articles-insights/coldzyme-joins-the-british-national-team/https://www.enzymatica.com/media/articles-insights/enzymatica-enters-partnership-with-the-uk-sports-institute/https://www.enzymatica.com/media/articles-insights/enzymatica-featured-in-biostock-new-partnership-with-the-uk-sports-institute/https://www.enzymatica.com/media/articles-insights/the-study-on-coldzyme-is-highlighted-on-national-tv-featured-on-tv4-efter-fem/https://www.enzymatica.com/media/articles-insights/sana-alajmovic-has-assumed-the-role-as-ceo-of-enzymatica/https://www.enzymatica.com/media/articles-insights/ceo-sana-alajmovic-on-enzymaticas-strategic-direction-and-future/https://www.enzymatica.com/media/articles-insights/biostock-interviews-enzymaticas-ceo-on-the-companys-next-phase-of-development/https://www.enzymatica.com/media/articles-insights/enzymaticas-presentation-at-stora-aktiedagarna-now-available-online/https://www.enzymatica.com/media/articles-insights/enzymaticas-ceo-on-the-road-ahead-for-coldzyme/https://www.enzymatica.com/media/articles-insights/enzymatica-and-stada-reunited-featured-in-biostock/https://www.enzymatica.com/media/media-contact/https://www.enzymatica.com/media/subscribe/https://www.enzymatica.com/contact/contact-us/https://www.enzymatica.com/contact/for-investors/https://www.enzymatica.com/contact/for-media/https://www.enzymatica.com/investors/prospectus/https://www.enzymatica.com/investors/prospectus/rights-issue-2014/https://www.enzymatica.com/investors/prospectus/rights-issue-2016/https://www.enzymatica.com/investors/enzymatica-on-first-north-growth-market/https://www.enzymatica.com/investors/investment-case/https://www.enzymatica.com/investors/risks/https://www.enzymatica.com/investors/the-share/https://www.enzymatica.com/investors/financial-reports/https://www.enzymatica.com/investors/presentations/https://www.enzymatica.com/investors/financial-calendar/https://www.enzymatica.com/investors/investor-relations-contact/https://www.enzymatica.com/career/https://www.enzymatica.com/sv/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2016/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2017/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2018/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2019/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2020/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2021/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2022/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2023/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstyrning/bolagsstyrningsrapport-2024/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2013/arsstamma-2013/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2014/extra-bolagsstamma-2014-03-06/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2014/arsstamma-2014/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2014/extra-bolagsstamma-2014-12-19/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2015/arsstamma-2015/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2016/extra-bolagsstamma-15-februari-2016/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2016/extra-bolagsstamma-14-april-2016/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2016/arsstamma-2016/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2016/extra-bolagsstamma-19-december-2016/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2017/arsstamma-2017/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2017/extra-bolagsstamma-25-oktober-2017/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2018/arsstamma-2018/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2018/extra-bolagsstamma-5-november-2018/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2019/arsstamma-2019/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2020/arsstamma-2020/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2021/arsstamma-2021/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2021/extra-bolagsstamma-18-oktober-2021/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2022/arsstamma-2022/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2023/arsstamma-2023/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2024/arsstamma-2024/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2024/arsstamma-2024-2/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2025/arsstamma-2025/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2025/extra-bolagsstamma-2025/https://www.enzymatica.com/sv/bolagsstyrning/bolagsstammor/2026/arsstamma-2026/https://www.enzymatica.com/sv/bolagsstyrning/valberedning/https://www.enzymatica.com/sv/bolagsstyrning/styrelse/https://www.enzymatica.com/sv/bolagsstyrning/riktlinjer-for-ersattning/https://www.enzymatica.com/sv/bolagsstyrning/bolagsordning/https://www.enzymatica.com/sv/forskning/oberoende-studier/https://www.enzymatica.com/sv/forskning/forskningshistorik/https://www.enzymatica.com/sv/produkter/coldzyme/https://www.enzymatica.com/sv/produkter/enzymformulering/https://www.enzymatica.com/sv/forskning-utveckling-lp/https://www.enzymatica.com/sv/foretag/introduktion/https://www.enzymatica.com/sv/foretag/organisation/https://www.enzymatica.com/sv/foretag/historik/https://www.enzymatica.com/sv/foretag/uppforandekod/https://www.enzymatica.com/sv/foretag/hallbarhet/https://www.enzymatica.com/sv/integritetspolicy/https://www.enzymatica.com/sv/media/pressmeddelanden/https://www.enzymatica.com/sv/media/pressmeddelanden/2026/bokslutskommunike-2025-ny-vd-tar-vid-inleder-nasta-fas-i-enzymaticas-internationella-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2026/kallelse-till-arsstamma-2026-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2026/enzymatica-och-stada-tecknar-partnerskapsavtal-for-tyskland-och-osterrike/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kvartalsrapport-q32025-stark-utveckling-i-sverige-och-fortsatt-fokus-pa-internationell-etablering/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-utser-tillforordnad-cfo-under-overgangsperiod/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-blir-officiell-leverantor-till-svenska-skidskytteforbundet/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-inleder-samarbete-med-uk-sports-institute-for-att-stotta-idrottares-halsa-och-prestation/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-starker-sin-narvaro-inom-elitidrott-inleder-partnerskap-med-brittiska-gb-snowsport/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/coldzyme-lanserar-ny-frisk-smak-eucalyptus/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-rekryterar-holger-lembrer-som-ny-cfo/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/lank-till-repris-av-digital-presstraff-5-mars-2025/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/claus-egstrand-avgar-som-vd-for-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymaticas-cfo-therese-filmersson-lamnar-sin-roll/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kommunike-fran-arsstamma-i-enzymatica-ab-publ-den-7-maj-2025/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kvartalsrapport-q12025-enzymatica-starker-positionen-pa-hemmamarknader-och-fokuserar-pa-internationell-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-publicerar-arsredovisning-for-2024/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kallelse-till-arsstamma-2025-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kvartalsrapport-q22025-stark-utveckling-i-sverige-och-okad-internationell-aktivitet/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ-den-22-augusti-2025/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/sana-alajmovic-utses-till-ny-vd-for-enzymatica-ab/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/kallelse-till-extra-bolagstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/enzymatica-satsar-pa-tillvaxt-med-nyrekrytering-anna-soderlund-ansluter-som-senior-director-marketing-sales/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/bokslutskommunike-2024-stark-utveckling-pa-egna-marknader-forberedelser-for-internationell-tillvaxt/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/nya-oberoende-studier-visar-att-coldzyme-verkar-pa-grundorsaken-till-luftvagsinfektioner-och-minskar-antalet-sjukdagar-och-symtom/https://www.enzymatica.com/sv/media/pressmeddelanden/2025/inbjudan-till-presskonferens-5-mars-2025/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/kallelse-till-arsstamma-2024-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymatica-offentliggor-utfall-i-foretradesemissionen/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymaticas-munspray-coldzyme-erhaller-ce-certifiering-enligt-nya-eu-forordningen-mdr/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymatica-offentliggor-informationsmemorandum-med-anledning-av-foretradesemission-av-aktier/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymaticas-nyemission-ar-sakerstalld-till-100-procent/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/slutgiltiga-resultat-fran-oberoende-klinisk-studie-visar-att-coldzyme-forkortar-sjukdomsperioden-med-cirka-5-dagar-/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/bokslutskommunike-2023-vetenskapliga-och-regulatoriska-framsteg-skapar-internationellt-intresse/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/kommunike-fran-arsstamma-i-enzymatica-ab-publ-den-7-maj-2024/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymaticas-styrelse-uppdaterar-de-finansiella-malen/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/kallelse-till-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/styrelsen-i-enzymatica-beslutar-om-nyemission-om-cirka-130-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/interimsresultat-fran-oberoende-klinisk-studie-av-coldzyme-visar-att-sjukdomstiden-minskar-med-cirka-5-dagar/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/delarsrapport-q22024-enzymatica-bygger-momentum-for-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/delarsrapport-q12024-mdr-certifieringen-oppnar-stora-kommersiella-mojligheter/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ-den-6-augusti-2024/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymatica-publicerar-arsredovisning-for-2023/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/delarsrapport-q32024-fokus-pa-att-utveckla-befintliga-och-nya-marknader/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/prospekt-avseende-enzymaticas-foretradesemission-offentliggjort/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/rapporterade-resultat-for-sekundara-effektmatt-fran-university-of-kents-studie-av-coldzyme-visar-signifikant-minskning-av-symtom-forlorade-traningsdagar-och-virusmangd/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/enzymatica-offentliggor-tillaggsprospekt/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/enzymatica-byter-certified-adviser-till-carnegie-investment-bank-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/kvartalsrapport-q32023-forskningsresultat-som-forandrar-spelplanen/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/kallelse-till-arsstamma-2023-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/kvartalsrapport-q42022-ett-ar-som-lade-grunden-for-tillvaxt/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/kvartalsrapport-q22023-en-spannande-och-viktig-tid-framover/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/delrapport-fran-klinisk-studie-coldzyme-minskar-signifikant-mangden-rhinovirus-samt-symptom-pa-halsont/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/ny-studie-coldzyme-bryter-infektionscykeln-och-minskar-mangden-influensavirus-signifikant/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/kvartalsrapport-q12023-stark-start-pa-aret--enzymaticas-tillvaxtresa-fortsatter-enligt-plan/https://www.enzymatica.com/sv/media/pressmeddelanden/2023/enzymatica-publicerar-arsredovisning-for-2022/https://www.enzymatica.com/sv/media/pressmeddelanden/2024/styrelsen-i-enzymatica-beslutar-om-nyemission-om-27-4-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymatica-och-university-of-kent-startar-studie-for-att-undersoka-hur-elitidrottare-kan-forebygga-virusinfektioner-i-de-ovre-luftvagarna/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/kvartalsrapport-q32022-en-bredare-roll-for-coldzyme-adderar-potential-for-framtiden/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/ny-studie-bekraftar-coldzyme-hindrar-virus-som-orsakar-covid-19-fran-att-fasta-vid-manskliga-luftvagsceller/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymatica-offentliggor-utfall-i-foretradesemissionen/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymatica-offentliggor-tillaggsprospekt/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/coldzyme-blockerar-aven-omikronvarianterna-ba4-och-ba5/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/prospekt-avseende-enzymaticas-foretradesemission-offentliggjort/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/kvartalsrapport-q22022-forbattrad-forsaljning-skapar-tillforsikt/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/styrelsen-i-enzymatica-beslutar-om-nyemission-om-747-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/coldzyme-blockerar-omikronvirus--enligt-ny-forskning/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymatica-tecknar-laneavtal-med-huvudagare/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/kommunike-fran-arsstamma-i-enzymatica-ab-publ-den-28-april-2022/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/kvartalsrapport-q12022-vara-finansiella-mal-ligger-fast/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/artikel-om-coldzyme-studie-frias-fran-misstankar-om-oredlighet-i-forskning/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymaticas-munspray-lanseras-i-turkiet/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymatica-publicerar-arsredovisning-for-2021/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/osterrikiska-forskare-visar-i-in-vitro-studie-att-coldzyme-blockerar-viruset-bakom-covid-19/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/kallelse-till-arsstamma-2022-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymaticas-munspray-lanseras-i-mexiko/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/bokslutskommunike-tydliga-tecken-pa-gynnsamma-trender-i-marknaden-efter-ett-utmanande-2021/https://www.enzymatica.com/sv/media/pressmeddelanden/2022/enzymatica-kommenterar-felaktiga-formuleringar-i-dagens-medicin/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/den-langsiktiga-planen-star-fast-i-en-utmanande-tid/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymaticas-styrelse-faststaller-finansiella-mal/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/kallelse-till-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/korrigering-av-tidigare-pressmeddelande-claus-egstrand-tilltrader-som-vd-tidigare-an-beraknat/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/claus-egstrand-tilltrader-som-vd-tidigare-an-beraknat/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/kinesiska-och-amerikanska-patentverken-avser-att-bevilja-patent-for-nyckelkomponent-i-forkylningsprodukten-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/fortsatt-lagre-forsaljning-till-foljd-av-pandemin-men-viss-stabilisering/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/claus-egstrand-utsedd-till-ny-vd-for-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymatica-och-stada-utokar-avtalet-for-viruprotect-till-vietnam/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymatica-utser-ny-kvalitetschef-och-kommunikationschef/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymatica-offentliggor-utfall-i-foretradesemissionen/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymatica-lanserar-coldzyme-pa-amazon/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/patent-for-coldzyme-godkant-i-japan/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/prospekt-avseende-enzymaticas-foretradesemission-offentliggjort/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/kommunike-fran-arsstamma-i-enzymatica-ab-publ-den-5-maj-2021/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/lagre-forsaljning-till-foljd-av-pandemin-men-nyemission-sakerstaller-fortsatt-internationell-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymatica-publicerar-arsredovisningen-for-2020/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/kallelse-till-arsstamma-2021-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/styrelsen-i-enzymatica-beslutar-om-nyemission-om-591-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymaticas-forsaljning-och-resultat-paverkat-av-pandemin/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/positivt-rorelseresultat-och-nastan-fordubblad-forsaljning-for-det-fjarde-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/enzymatica-kommenterar-artikel-i-dagens-medicin/https://www.enzymatica.com/sv/media/pressmeddelanden/2021/nya-strategiska-rekryteringar-och-organisationsforandring-hos-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/stada-avtalet-utokat-med-norden/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-ingar-avtal-med-ms-pharma-for-mena/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/fortsatt-stark-forsaljningsokning-samt-positivt-kassaflode-under-det-tredje-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-ingar-avtal-med-sanofi-gallande-frankrike-och-italien-for-forkylningssprayen-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-och-stada-utokar-avtalet-for-viruprotect-till-ryssland-polen-ukraina-och-cis-lander/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/coldzyme-lanserad-i-israel/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/the-journal-of-medical-virology-har-granskat-godkant-och-publicerat-resultaten-fran-enzymaticas-in-vitro-studie-pa-sars-cov-2/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/nya-patent-godkanda-for-coldzyme-i-japan-och-ryssland/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/ny-version--rattad-den-17-september-2020-resultaten-fran-enzymaticas-placebokontrollerade-randomiserade-studie-visar-statistiskt-signifikant-kortare-forkylningar/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/resultaten-fran-enzymaticas-placebokontrollerade-randomiserade-studie-visar-statistiskt-signifikant-kortare-forkylningar-och-god-upplevd-behandlings-effekt-vid-anvandning-av-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/en-ny-in-vitro-studie-visar-att-coldzyme-deaktiverar-sars-cov-2-som-orsakar-covid-19-pandemin/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/fordubblad-forsaljning-aven-under-det-andra-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/kortare-forkylningar-for-elitidrottare-med-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-och-stada-utokar-avtalet-for-europa/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/europapatent-godkant-for-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/ledningsforandringar-i-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/fordubblad-forsaljning-och-positivt-resultat-under-det-forsta-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/coldzyme-far-klass-iii-godkannande-inom-eu/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-mojliggor-postrostning-vid-arsstamman-2020/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/kallelse-till-arsstamma-2020-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-publicerar-arsredovisningen-for-2019/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-far-okad-forsaljning-pa-grund-av-coronasituationen/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-tecknar-avtal-med-chemipal-for-israel/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/starka-resultat-fran-preventiv-anvandning-av-coldzyme-mot-forkylningsvirus/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/coldzyme--tredje-storsta-varumarke-i-sverige-inom-forkylning/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/kortare-forkylningar-och-mildare-symptom-hos-barn-som-anvander-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/europeiska-patentverket-avser-att-bevilja-ett-nytt-patent-for-en-nyckelkomponent-i-forkylningsprodukten-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/valberedningen-foreslar-fredrik-lindberg-till-enzymaticas-styrelse/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/enzymatica-ingar-avtal-med-keyuan-trade-for-kina/https://www.enzymatica.com/sv/media/pressmeddelanden/2020/coldzyme-lanserad-i-hong-kong/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/rattelse-enzymaticas-vd-avgar/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymaticas-vd-avgar/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymatica-sluter-avtal-om-leverans-av-enzymformuleringer-for-den-kinesiska-hudvardsmarknaden/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/utokat-samarbete-med-stada-i-tyskland/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/mycket-stark-forsaljningsokning-under-det-tredje-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymatica-rekryterar-ny-kvalitetschef/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/preliminara-resultat-fran-enzymaticas-placebokontrollerade-randomiserade-studie-uppfyllde-inte-det-primara-malet/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/coldzyme-lanseras-med-ny-smak-och-nya-produktpastaenden/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymatica-tecknar-kosmetika-avtal-till-ett-varde-av-120-msek-over-tre-ar-med-tyska-bolaget-maren/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/fortsatt-stark-tillvaxt-i-sverige-men-lagre-total-forsaljning-under-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/samtliga-patienter-rekryterade-till-enzymaticas-tyska-placebokontrollerade-multicenterstudie-med-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymaticas-forkylningsspray-lanserad-i-sydafrika/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymatica-ab-stark-forsaljning-under-fjarde-kvartalet-men-lagre-forsaljning-for-helaret-2018-orsakat-av-restriktioner-i-tyskland/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymatica-ab-forsta-patienterna-inkluderade-i-stor-placebokontrollerad-multicenterstudie-med-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2019/enzymatica-ab-resultat-fran-den-tyska-multicenterstudien-starker-och-breddar-coldzymes-produktpastaenden/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-avslag-for-overklagan-om-enzymaticas-forkylningsspray-i-tyskland/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymatica-tillfors-987-msek-efter-avslutad-nyemission/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-sluter-ytterligare-avtal-i-asien-med-evergreen-for-hong-kong--macau/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-prospekt-avseende-enzymaticas-foretradesemission-offentliggjort/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymaticas-foretradesemission-ar-sakerstalld-till-100-procent/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/ny-brittisk-studie-pa-elitidrottare-visar-pa-kortare-forkylningar-med-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-genombrottsavtal-for-japan-och-lagre-forsaljning-i-q3-pa-grund-av-restriktioner-i-tyskland/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-kallelse-till-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-styrelsen-i-enzymatica-ab-beslutar-om-foretradesemission-om-987-mkr/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymatica-tecknar-avtal-for-den-japanska-marknaden/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-signifikanta-fordelar-med-coldzyme-i-en-stor-tysk-multicenterstudie-for-utvardering-av-olika-skalor-for-forkylningssymptom/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-domen-mot-enzymaticas-forkylningsspray-i-tyskland-overklagas/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymatica-sluter-avtal-om-coldzyme-med-abex-pharmaceuticals-for-sydafrika/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-lagre-forsaljning-under-q2-men-31--okning-for-det-forsta-halvaret/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-domstolsutslag-lagger-restriktioner-pa-enzymaticas-forkylningsspray-i-tyskland/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymatica-sakerstaller-finansiering-av-verksamheten/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymatica-sluter-avtal-med-qualia-pharma-for-grekland-och-cypern/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-kommunike-fran-arsstamma-2018-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-fortsatt-tillvaxt-under-det-forsta-kvartalet/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab--nya-resultat-fran-enzymaticas-in-vitro-studie-coldzyme-inaktiverar-aven-coronavirus/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-ny-coldzyme-studie-pa-elitidrottare-bekraftar-forebyggande-och-forkortande-effekt/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-enzymatica-publicerar-arsredovisningen-for-2017/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-kallelse-till-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2018/enzymatica-ab-stark-tillvaxt-och-internationellt-genombrott-under-2017/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/ny-kundundersokning--coldzyme-forebygger-forkylning-och-mildrar-eller-forkortar-den-om-man-anda-drabbas/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-enzymaticas-valberedning-for-arsstamman-2018-utsedd/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-enzymatica-presenterar-resultat-av-studie-coldzyme-har-formaga-att-oskadliggora-vanliga-forkylningsvirus/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-studie-om-coldzyme---den-mest-rekommenderade-forkylningsprodukten-hos-apoteken/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-delarsrapport-for-enzymatica-ab-publ-januari--september-2017/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-fullstandiga-artikeln-fran-coldprev-i-studien-publicerad---starker-dokumentation-for-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-coldzyme-forkylningsspray-minskar-sjukfranvaron-hos-forskolepersonal/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-kallelse-till-extra-bolagsstamma-angaende-bland-annat-personaloptionsprogram-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-rekryterar-finanschef/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-fortsatt-forsaljningsokning-och-genombrottsorder-fran-stada/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-rekryterar-chief-commercial-officer/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-rekryterar-chief-operating-officer/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/studie-pa-elitidrottare-visar-att-coldzyme-skyddar-genom-att-ge-farre-sjuk--och-forlorade-traningsdagar-samt-forbattrad-livskvalitet/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-far-rekordorder-fran-tyska-stada/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/bengt-jondell-fortsatter-som-t-f-cfo/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-kommunike-fran-arsstamma-2017-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-genombrott-i-tyskland-och-fortsatt-okande-forsaljning/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-enzymatica-publicerar-arsredovisningen-for-2016/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-komplettering-av-valberedningens-i-enzymatica-ab-forslag-infor-arsstamman-2017-avseende-val-av-revisor/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-kallelse-till-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-abgeografisk-expansion-och-fortsatt-tillvaxt-under-2016/https://www.enzymatica.com/sv/media/pressmeddelanden/2017/enzymatica-ab-enzymatica-ingar-samarbetsavtal-med-stada-arzneimittel-ag/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/coldzyme-visar-pa-minskade-sjukskrivningar-under-forkylningssasongen/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-resultat-fran-experimentell-forkylningsstudie/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-kallelse-till-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-extra-bolagsstamma-om-forandringar-i-styrelsen/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/medicinsk-fallrapport-om-lovande-behandling-med-coldzyme-hos-patient-med-primar-immunbrist/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-fortsatt-god-forsaljningsutveckling-for-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-enzymatica-tecknar-distributionssavtal-med-endeavour-consumer-health-for-australiennya-zeeland/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-styrelsen-i-enzymatica-beslutar-om-riktad-nyemission-om-403-miljoner-kronor/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-god-volymutveckling-for-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymaticas--foretradesemission-avslutad---tillfors-60-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymaticas-insynspersoner-avser-teckna-for-16-msek-i-nyemissionen/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kallelse-till-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kundstudier-coldzyme-anvandare-agerar-tidigt-och-aktivt-vid-forkylning/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/diagram-kundnojdhetsundersokning-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/information-om-enzymaticas-nyemission/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-publicerar-prospekt/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-publicerar-arsredovisningen-for-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/delarsrapport-for-enzymatica-ab-publ-januari-mars-2016/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-slutfor-forvarvet-av-zymetech-med-tilltrade-for-nya-styrelseledamoter-och-representant-i-valberedningen/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/narings--och-innovationsministern-traffar-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/tillforordnad-cfo-for-enzymatica-utsedd/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-uppdaterad-tidsplan-for-forvarvet-av-zymetech-och-foretradesemissionen/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-offentliggor-nya-datum-for-den-finansiella-informationen/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kallelse-till-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/styrelsen-i-enzymatica-beslutar-om-foretradesemission-om-60-miljoner-sek/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/mobiler-och-surfplattor-fulla-av-bakterier-och-virus--sa-sallan-rengor-vi-vara-smartphones-och-surfplattor/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/coldzyme-lanserat-i-spanien-och-har-fatt-god-tackning-i-finland/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ-2016-02-15/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ab-stark-tillvaxt-under-2015-och-forvarv-for-internationell-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-tidigarelagger-sin-bokslutskommunike-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/stammohandlingar-for-extra-bolagsstamma-den-15-februari-2016/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/intervju-med-fredrik-lindberg-angaende-forvarvet-av-zymetech/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/inbjudan-till-presentation-om-enzymaticas-forvarv-av-zymetech/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/kallelse-till-extra-bolagsstamma-i-enzymatica-ab-publ-2016-01-28/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/vanliga-fragor-och-svar-angaende-enzymaticas-forvarv-av-zymetech/https://www.enzymatica.com/sv/media/pressmeddelanden/2016/enzymatica-ingar-avtal-om-forvarv-och-forbereder-internationell-expansion-genom-nyemission/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-fortydligande-angaende-artikel-i-media/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-tecknar-distributionssavtal-med-esteve-i-spanien/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-tecknar-distributionsavtal-med-tamro-for-den-finska-marknaden/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-tecknar-distributionsavtal-med-tamro-for-den-finska-marknaden-2015-11-10/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/intervju-med-vd-fredrik-lindberg-om-q3-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-ab-delarsrapport-for-enzymatica-ab-publ-januari-september-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-starker-narvaron-i-storbritannien-genom-samarbete-med-apotekskedjan-lloyds/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-delarsrapport-for-enzymatica-ab-publ-januari-juni-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-ringde-in-bolaget-pa-nasdaq-first-north/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-har-godkants-for-listning-pa-nasdaq-first-north--handelsstart-den-15-juni-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/intervju-med-vd-fredrik-lindberg-om-q1-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-delarsrapport-for-enzymatica-ab-publ-januari-mars-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/valberedningen-i-enzymatica-lamnar-reviderat-styrelseforslag-som-stods-av-bolagets-huvudagare/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-meddelande-angaende-forslag-infor-arsstamma/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-valberedningens-forslag-till-styrelse/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-filmad-bolagspresentation-lund/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-publicerar-arsredovisningen-for-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/meddelande-angaende-forslag-infor-arsstamman/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-lanserar-forkylningssprayen-coldzyme-onecold-pa-svenska-apotek/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/kallelse-till-arsstamma-i-enzymatica-ab/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/enzymatica-utser-valberedning/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/information-om-enzymaticas-strategi-for-internationell-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/valkommen-att-lyssna-pa-enzymaticas-nya-vd-fredrik-lindberg/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/tv-klipp-om-coldzyme-slipp-forkylningar--losningen-hittades-i-torsken/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/intervju-med-vd-fredrik-lindberg-om-q4-och-helaret-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/bokslutskommunike-2014-for-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/fredrik-lindberg-pa-plats-som-ny-vd-pa-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/meddelande-angaende-forslag-infor-arsstamma-den-21-april-2015/https://www.enzymatica.com/sv/media/pressmeddelanden/2015/torstein-klar-for-world-cup-i-skidskytte-i-italien/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/extra-bolagsstamma-i-enzymatica-ab-installd/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/kallelse-till-extra-bolagsstamma-i-enzymatica-ab/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/fredrik-lindberg-ny-vd-for-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/intervju-med-vd-christian-w-jansson-om-q3-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/delarsrapport-for-enzymatica-ab-publ-januari-september-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/coldzyme-expanderar-till-hela-skandinavien-genom-dansk-lansering/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-far-sin-forsta-order-pa-veterinarprodukter-fran-sin-partner-i-nordamerika/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/ny-styrelseordforande-i-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-utser-tillforordnad-vd/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymaticas-veterinarprodukter-lanseras-pa-massan-avma-annual-convention-i-denver-usa/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/delarsrapport-for-enzymatica-ab-publ-januari-juni-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-coldzyme-introduceras-i-storbritannien/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-coldzyme-introduceras-pa-apoteken-i-norge/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-presenterar-coldprev-studien-pa-vetenskaplig-kongress-i-kopenhamn/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/delarsrapport-for-enzymatica-ab-publ-januari-mars-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/fortydligande-aktieagares-forslag-infor-arsstamman-2014-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-publicerar-arsredovisningen-for-2013/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-forstarker-forsaljningsorganisationen/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/nytt-datum-for-enzymaticas-delarsrapport-jan-mars-19-maj-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/kallelse-till-arsstamma-i-enzymatica-ab/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/fullmakt-arsstamma-2014/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymaticas-foretradesemission-overtecknad/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/anvandning-av-coldzyme-munspray-kan-ge-stora-samhallsekonomiska-vinster/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/prospekt_enzymatica-ab_140310_556719-9244/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzy_sarskild_anmalningssedel/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzy_anmalningssedel-utan-tr/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-offentliggor-prospekt-i-anledning-av-forestaende-nyemission/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/kommunike-fran-extra-bolagsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/kallelse-till-extra-bolagsstamma-i-enzymatica-ab-2014-02-17/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-foreslar-beslut-om-foretradesemission-om-totalt-cirka-63-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-tecknar-avtal-for-forsaljning-av-coldzyme-pa-svenska-flygplatser/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-offentliggor-lanseringsplan-for-egenutvecklad-munskoljsprodukt-mot-tandkottsinflammation/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/bokslutskommunike-for-enzymatica-ab-publ-januari--december-2013/https://www.enzymatica.com/sv/media/pressmeddelanden/2014/enzymatica-forstarker-organisationen/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-okar-omsattningen-for-2013-langt-over-sitt-finansiella-mal/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-gar-sjalv-i-skandinavien-och-med-partners-internationellt/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-far-full-marknadstackning-genom-grossistavtal-med-tamro/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/kvinnor-och-unga-besvaras-mest-av-forkylningar/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/rapport-forkylning-novus/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/delarsrapport-for-enzymatica-ab-publ-januari--september-2013/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-startar-nytt-produktomrade-och-etablerar-dotterbolag-i-usa/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-avtal-om-coldzyme-munspray-pa-apotekskedjan-medstops-hyllor/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-genomfor-en-riktad-emission-pa-ca-19-mkr/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/coldprev-studien-coldzyme-munspray-reducerar-bade-virusmangd-och-antal-forkylningsdagar-hos-infekterade-jamfort-med-placebo/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/coldzyme-munspray-lanseras-brett-snart-pa-apoteket-abs-hyllor/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica---intervju-med-bolagets-vd-och-actavis-nordiska-marknadschef/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-sluter-avtal-med-actavis-for-coldzyme-i-norden/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/delarsrapport-for-enzymatica-ab-publ-januari--mars-2013/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/post-marketing-surveillance-8-av-10-pa-coldzyme-munspray-slapp-forkylning-helt/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/ett-unikt-och-tidsbegransat-erbjudande-fran-enzymatica---team-coldzyme/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-arsredovisning-for-rakenskapsaret-2012/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-paborjar-process-for-notering-pa-stockholmsborsen/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/kallelse-till-arsstamma-i-enzymatica-ab/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/fullmakt/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/anders-jungbeck-foreslas-till-ny-styrelseledamot-for-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/christian-w-jansson-foreslas-till-ny-ordforande-for-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/nytt-datum-for-enzymaticas-arsstamma/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/stoppa-forkylningen-med-coldzyme-munspray/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/bokslutskommunike-for-enzymatica-ab-januari---december-2012/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/artikel-i-senaste-numret-av-filter-om-coldzyme-munspray-mot-forkylning/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/sveriges-radio-p4---intervju-om-coldzyme-munspray-mot-forkylning/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-inleder-klinisk-marknadsuppfoljningsstudie-for-prevention-och-forkortande-av-ovre-luftvagsinfektion/https://www.enzymatica.com/sv/media/pressmeddelanden/2013/enzymatica-coldzyme-munspray-mot-forkylning-introduceras-pa-apotek-hjartat/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/en-dusch-i-munnen-tar-knacken-pa-forkylningen-artikel-aret-runt-522012/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-sluter-avtal-med-kronans-droghandel-apotekskedja/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/interim-report-for-enzymatica-ab-july-1-2012-to-september-30-2012/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/kvartalsrapport-for-enzymatica-ab_2012-07-01-till-2012-09-30/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/fredrik-hakansson-ny-cfo-pa-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/mats-clarsund-ny-forsknings--och-utvecklingschef-pa-enzymatica/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-utser-scientific-advisory-board/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/sista-dag-for-handel-med-enzymaticas-bta/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/kvartalsrapport-for-enzymatica-ab_2012-04-01-till-2012-06-30/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymaticas-coldzyme-munspray-mot-forkylning-registrerad-hos-lakemedelsverket/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymaticas-foretradesemission-kraftigt-overtecknad/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-genomfor-studie-med-new-hair-clinic-i-lund-efter-beviljat-internationellt-studie-anslag/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymaticas-pagaende-emission-teckningsataganden-visavi-anmalningssedel-teckningssedel/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-ab-publ-presenterar-pa-smabolagsdagen/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/anmalningssedel/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-sarskild-anmalningssedel-2-utan-foretrade/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/inbjudan-till-teckning-av-aktier-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/kvartalsrapport-for-enzymatica-ab-2012-01-01-till-2012-03-31/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-genomfor-foretradesemission-om-cirka-82-msek/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymaticas-riktade-emission-fulltecknad/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-registrerar-perizyme-som-medicintekniskt-tuggummi/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-genomfor-nyemission-for-fortsatt-expansion/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/elitidrottare-mycket-nojda-med-anvandning-av-coldzyme-munspray/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/kommunike-fran-arsstamma-i-enzymatica-ab-publ/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymaticas-styrelse-och-ledning-forvarvar-aktiepost/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymaticas-arsredovisning-for-rakenskapsaret-2011-05-01--2011-12-31/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-kallelse-till-arsstamma/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-bokslutskommunike-for-enzymatica-ab-2011-05-01-till-2011-12-31/https://www.enzymatica.com/sv/media/pressmeddelanden/2012/enzymatica-kommunike-fran-extra-bolagsstamma-2012-01-24/https://www.enzymatica.com/sv/media/artiklar-insikter/https://www.enzymatica.com/sv/media/artiklar-insikter/lansering-i-mexiko/https://www.enzymatica.com/sv/media/artiklar-insikter/lansering-i-turkiet/https://www.enzymatica.com/sv/media/artiklar-insikter/marknadskampanj-i-sverige/https://www.enzymatica.com/sv/media/artiklar-insikter/intervju-med-vd-claus-egstrand/https://www.enzymatica.com/sv/media/artiklar-insikter/positiva-resultat-i-ny-studie-om-influensa/https://www.enzymatica.com/sv/media/artiklar-insikter/intervju-med-prof-doris-wilflingseder-om-hennes-nya-studie-om-coldzyme/https://www.enzymatica.com/sv/media/artiklar-insikter/coldzyme-minskar-mangden-rhinovirus-och-symptom-pa-halsont-enligt-ny-studie/https://www.enzymatica.com/sv/media/artiklar-insikter/coldzyme-i-amerikanska-morgonshowen-the-balancing-act/https://www.enzymatica.com/sv/media/artiklar-insikter/coldzyme-i-reklamen-under-10-ar/https://www.enzymatica.com/sv/media/artiklar-insikter/resultat-fran-coldzyme-studie-presenterade-vid-olympisk-konferens/https://www.enzymatica.com/sv/media/artiklar-insikter/abctract-om-klinisk-coldzyme-studie-publicerat-i-british-journal-of-sports-medicine/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymatica-deltar-i-global-heath-campaign/https://www.enzymatica.com/sv/media/artiklar-insikter/professor-glen-davison-talade-vid-global-health-summit/https://www.enzymatica.com/sv/media/artiklar-insikter/biostock-om-de-rapporterade-slutgiltiga-studieresultaten-coldzyme-forkortar-sjukdomstiden-och-lindrar-symtom/https://www.enzymatica.com/sv/media/artiklar-insikter/powered-by-penzyme/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymaticas-vd-kommenterar-sbus-rapport/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymaticas-resultat-publiceras-i-the-journal-of-physiology/https://www.enzymatica.com/sv/media/artiklar-insikter/repris-av-presskonferens-om-coldzyme-den-5-mars-2025/https://www.enzymatica.com/sv/media/artiklar-insikter/lakartidningen-uppmarksammar-coldzyme/https://www.enzymatica.com/sv/media/artiklar-insikter/intervju-med-vd-claus-egstrand-om-q1-2025-av-biostock/https://www.enzymatica.com/sv/media/artiklar-insikter/vd-claus-egstrand-enzymatica-pa-redeyes-temadag-om-medtech-/https://www.enzymatica.com/sv/media/artiklar-insikter/professorerna-bakom-studierna-om-coldzyme-intervjuas-i-biostock/https://www.enzymatica.com/sv/media/artiklar-insikter/ny-hemsida-for-coldzyme-med-fokus-pa-vetenskap-och-forstaelse-for-forkylning/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymatica-i-nytt-partnerskap-med-svenska-skidskytteforbundet/https://www.enzymatica.com/sv/media/artiklar-insikter/vinn-snabbare-over-forkylningen-coldzymes-nya-kampanj/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymatica-lanserar-coldzyme-eucalyptus/https://www.enzymatica.com/sv/media/artiklar-insikter/coldzyme-tar-plats-i-brittiska-landslaget/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymatica-inleder-samarbete-med-uk-sports-institute/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymatica-i-biostock-nytt-samarbete-med-uk-sports-institute/https://www.enzymatica.com/sv/media/artiklar-insikter/studien-om-coldzyme-uppmarksammas-i-nationell-tv-lyfts-fram-i-tv4-efter-fem/https://www.enzymatica.com/sv/media/artiklar-insikter/sana-alajmovic-har-tilltratt-som-vd-for-enzymatica/https://www.enzymatica.com/sv/media/artiklar-insikter/vdn-sana-alajmovic-om-enzymaticas-strategiska-inriktning-och-framtid/https://www.enzymatica.com/sv/media/artiklar-insikter/biostock-intervjuar-enzymaticas-vd-om-nasta-fas-i-bolagets-utveckling/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymaticas-presentation-fran-stora-aktiedagarna-finns-nu-tillganglig/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymaticas-vd-om-vagen-framat-for-coldzyme/https://www.enzymatica.com/sv/media/artiklar-insikter/enzymatica-och-stada-aterforenade-las-mer-i-biostock/https://www.enzymatica.com/sv/media/mediekontakt/https://www.enzymatica.com/sv/media/prenumerera/https://www.enzymatica.com/sv/kontakt/kontakta-oss/https://www.enzymatica.com/sv/kontakt/for-investerare/https://www.enzymatica.com/sv/kontakt/for-media/https://www.enzymatica.com/sv/investerare/prospekt/https://www.enzymatica.com/sv/investerare/prospekt/prospekt-2014/https://www.enzymatica.com/sv/investerare/prospekt/nyemission-april-2016/https://www.enzymatica.com/sv/investerare/enzymatica-pa-first-north-growth-market/https://www.enzymatica.com/sv/investerare/investment-case/https://www.enzymatica.com/sv/investerare/risker/https://www.enzymatica.com/sv/investerare/aktien/https://www.enzymatica.com/sv/investerare/finansiella-rapporter/https://www.enzymatica.com/sv/investerare/presentationer/https://www.enzymatica.com/sv/investerare/finansiell-kalender/https://www.enzymatica.com/sv/investerare/investor-relations-kontakt/https://www.enzymatica.com/sv/karriar/